These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 36901916)

  • 41. Apigenin inhibits the inducible expression of programmed death ligand 1 by human and mouse mammary carcinoma cells.
    Coombs MRP; Harrison ME; Hoskin DW
    Cancer Lett; 2016 Oct; 380(2):424-433. PubMed ID: 27378243
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Positive and Negative Immunoregulatory Role of B7 Family: Promising Novel Targets in Gastric Cancer Treatment.
    Bolandi N; Derakhshani A; Hemmat N; Baghbanzadeh A; Asadzadeh Z; Afrashteh Nour M; Brunetti O; Bernardini R; Silvestris N; Baradaran B
    Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639059
    [TBL] [Abstract][Full Text] [Related]  

  • 43. eIF5B regulates the expression of PD-L1 in prostate cancer cells by interacting with Wig1.
    Li Q; Xiao M; Shi Y; Hu J; Bi T; Wang C; Yan L; Li X
    BMC Cancer; 2021 Sep; 21(1):1022. PubMed ID: 34525951
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinicopathological correlation of PD-L1 expression in primary and metastatic breast cancer and infiltrating immune cells.
    Tawfik O; Kimler BF; Karnik T; Shehata P
    Hum Pathol; 2018 Oct; 80():170-178. PubMed ID: 29936058
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tumor suppressive activity of miR-424-5p in breast cancer cells through targeting PD-L1 and modulating PTEN/PI3K/AKT/mTOR signaling pathway.
    Dastmalchi N; Hosseinpourfeizi MA; Khojasteh SMB; Baradaran B; Safaralizadeh R
    Life Sci; 2020 Oct; 259():118239. PubMed ID: 32784058
    [TBL] [Abstract][Full Text] [Related]  

  • 46. PD-L1 expression is increased in a subset of basal type breast cancer cells.
    Soliman H; Khalil F; Antonia S
    PLoS One; 2014; 9(2):e88557. PubMed ID: 24551119
    [TBL] [Abstract][Full Text] [Related]  

  • 47. PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes.
    Ali HR; Glont SE; Blows FM; Provenzano E; Dawson SJ; Liu B; Hiller L; Dunn J; Poole CJ; Bowden S; Earl HM; Pharoah PD; Caldas C
    Ann Oncol; 2015 Jul; 26(7):1488-93. PubMed ID: 25897014
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The Expression Level of
    Masuda T; Noda M; Kitagawa A; Hu Q; Fujii A; Ito S; Kosai K; Ando Y; Matsumoto Y; Ohtsu H; Uchida H; Ohno S; Mimori K
    Anticancer Res; 2020 Jul; 40(7):3733-3742. PubMed ID: 32620612
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Association of PD-1, PD-L1, and CTLA-4 Gene Expression and Clinicopathologic Characteristics in Patients With Non-Small-Cell Lung Cancer.
    Lafuente-Sanchis A; Zúñiga Á; Estors M; Martínez-Hernández NJ; Cremades A; Cuenca M; Galbis JM
    Clin Lung Cancer; 2017 Mar; 18(2):e109-e116. PubMed ID: 27816393
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

  • 51. TLR9 Mediated Tumor-Stroma Interactions in Human Papilloma Virus (HPV)-Positive Head and Neck Squamous Cell Carcinoma Up-Regulate PD-L1 and PD-L2.
    Baruah P; Bullenkamp J; Wilson POG; Lee M; Kaski JC; Dumitriu IE
    Front Immunol; 2019; 10():1644. PubMed ID: 31379843
    [No Abstract]   [Full Text] [Related]  

  • 52. Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFNγ secretion.
    Chaganty BKR; Qiu S; Gest A; Lu Y; Ivan C; Calin GA; Weiner LM; Fan Z
    Cancer Lett; 2018 Aug; 430():47-56. PubMed ID: 29746929
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tumor-derived PD1 and PD-L1 could promote hepatocellular carcinoma growth through autophagy induction in vitro.
    Chen Z; Liu S; Xie P; Zhang B; Yu M; Yan J; Jin L; Zhang W; Zhou B; Li X; Xiao Y; Xu Y; Ye Q; Li H; Guo L
    Biochem Biophys Res Commun; 2022 May; 605():82-89. PubMed ID: 35316767
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immune signature of metastatic breast cancer: Identifying predictive markers of immunotherapy response.
    Kim JY; Lee E; Park K; Park WY; Jung HH; Ahn JS; Im YH; Park YH
    Oncotarget; 2017 Jul; 8(29):47400-47411. PubMed ID: 28537889
    [TBL] [Abstract][Full Text] [Related]  

  • 55. PD-L1, B7-H3 and VISTA are highly expressed in gestational trophoblastic neoplasia.
    Zong L; Zhang M; Wang W; Wan X; Yang J; Xiang Y
    Histopathology; 2019 Sep; 75(3):421-430. PubMed ID: 31013360
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer.
    Wescott EC; Sun X; Gonzalez-Ericsson P; Hanna A; Taylor BC; Sanchez V; Bronzini J; Opalenik SR; Sanders ME; Wulfkuhle J; Gallagher RI; Gomez H; Isaacs C; Bharti V; Wilson JT; Ballinger TJ; Santa-Maria CA; Shah PD; Dees EC; Lehmann BD; Abramson VG; Hirst GL; Brown Swigart L; van ˈt Veer LJ; Esserman LJ; Petricoin EF; Pietenpol JA; Balko JM
    Cancer Res Commun; 2024 Apr; 4(4):1120-1134. PubMed ID: 38687247
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity.
    Tanegashima T; Togashi Y; Azuma K; Kawahara A; Ideguchi K; Sugiyama D; Kinoshita F; Akiba J; Kashiwagi E; Takeuchi A; Irie T; Tatsugami K; Hoshino T; Eto M; Nishikawa H
    Clin Cancer Res; 2019 Aug; 25(15):4808-4819. PubMed ID: 31076547
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Anti-PD-L1 × anti-CD3 bispecific T-cell engager-armed T cells can overcome immunosuppression and redirect T cells to kill breast cancer cells expressing PD-L1.
    Luangwattananun P; Sangsuwannukul T; Supimon K; Thuwajit C; Chieochansin T; Sa-Nguanraksa D; Samarnthai N; O-Charoenrat P; Junking M; Yenchitsomanus PT
    Int Immunopharmacol; 2023 Nov; 124(Pt B):111012. PubMed ID: 37804657
    [TBL] [Abstract][Full Text] [Related]  

  • 59. MAPK pathway activity plays a key role in PD-L1 expression of lung adenocarcinoma cells.
    Stutvoet TS; Kol A; de Vries EG; de Bruyn M; Fehrmann RS; Terwisscha van Scheltinga AG; de Jong S
    J Pathol; 2019 Sep; 249(1):52-64. PubMed ID: 30972766
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Trastuzumab upregulates programmed death ligand-1 expression through interaction with NK cells in gastric cancer.
    Yamashita K; Iwatsuki M; Yasuda-Yoshihara N; Morinaga T; Nakao Y; Harada K; Eto K; Kurashige J; Hiyoshi Y; Ishimoto T; Nagai Y; Iwagami S; Baba Y; Miyamoto Y; Yoshida N; Ajani JA; Baba H
    Br J Cancer; 2021 Feb; 124(3):595-603. PubMed ID: 33100329
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.